Table 5 The clinical trials of CAR-NK cell-based therapy for hematological malignancies and solid tumors
From: Natural killer cells: a promising immunotherapy for cancer
| Cancer type | ClinicalTrials.gov Identifier | Initial time | Phase | N | Primary study endpoint |
|---|---|---|---|---|---|
| R/R Non-Hodgkin Lymphoma |
NCT04639739 CD19 | December 17, 2020 | Phase I | 9 |
Incidence of dose limiting toxicity Incidence and severity of AEs and SAEs |
| Relapsed and Refractory B Cell Lymphoma |
NCT03692767 CD22 | March 2019 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
| Relapsed and Refractory B Cell Lymphoma |
NCT03690310 CD19 | March 2019 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
| Epithelial Ovarian Cancer |
NCT03692637 Mesothelin | March 2019 | Phase I | 30 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
| metastatic Solid Tumours |
NCT03415100 NKG2D-ligand | January 2, 2018 | Phase I | 30 | Number of Adverse Events |
| Castration-Resistant Prostate Cancer |
NCT03692663 PSMA | December 2018 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
| Solid Tumors |
NCT03940820 ROBO1 | May 2019 | Phase I/II | 20 | Occurrence of treatment related adverse events as assessed by CTCAE v4.03 |
| Relapse/Refractory MM |
NCT03940833 BCMA | May 2019 | Phase I/II | 20 | Occurrence of treatment related adverse events as assessed by CTCAE v4.03 |
| Recurrent/Metastatic Gastric or Head and Neck Cancer |
NCT04847466 Irradiated PD-L1 | April 22, 2021 | Phase II | 55 | ORR |
| Relapsed and Refractory B Cell Lymphoma |
NCT03824964 CD19/CD22 | February 1, 2019 | Phase I | 10 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
| B Lymphoid Malignancies |
NCT04796675 CD19 | April 10, 2021 | Phase I | 27 | Incidence of Treatment-related Adverse Events |
| Relapsed/Refractory CD33 + AML |
NCT02944162 CD33 | October 2016 | Phase I/II | 10 | Adverse events attributed to the administration of the anti-CD33 CAR-NK cells |
| CD19 Positive Leukemia and Lymphoma |
NCT02892695 CD19 | September 2016 | Phase I | 10 | Adverse events attributed to the administration of the anti-CD19 CAR-NK cells |
| Pancreatic Cancer |
NCT03941457 ROBO1 | May 2019 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.03 |
| CD19 + Relapsed/Refractory Hematological Malignancies |
NCT04796688 CD19 | March 10, 2021 | Phase I | 27 | Incidence of Treatment-related Adverse Events |
| Relapsed/Refractory B-Lymphoid Malignancies |
NCT03056339 CD19 | June 21, 2017 | Phase I/II | 36 | Toxicity and efficacy |